(Available Soon)

CSE: BUX | OTCQB: BMKDF | FSE: 20B

BioMark Diagnostics Inc.

Empowering early detection. Transforming cancer care.

Who We Serve

Clinicians & Screening Programs

A blood-based metabolic test that complements LDCT in high-risk populations. By stratifying patient risk, it can help guide who to prioritize for LDCT and support follow-up decisions on indeterminate findings, with the potential to improve specificity and broaden access to early lung cancer detection. Several studies are being completed and others being introduced.

Clinical data & use cases

Research & Biopharma Partners

We offer clinical trial services that apply metabolic profiling to companion diagnostics, treatment response monitoring and recurrence detection. We also welcome collaborative research, including multi-modal studies that combine metabolic data with imaging, genomic or clinical data.
Partner with us.

Partnering opportunities

Scientific Community

Peer-reviewed publications demonstrating high AUROC performance for early-stage lung cancer detection using plasma metabolomics + ML.

Publications & posters

Company Information

Corporate details, investment highlights, and contact for med-tech interested parties.

Investment & filings

BioMark's Mission

To make cancer risk measurable at the first point of care, giving clinicians the clarity to know who needs further investigation and how to act on what they find.

Science Snapshot

Downstream metabolic signatures provide amplified, accessible signals for early detection.

Metabolomics + Machine Learning

Metabolomics + Machine Learning

Analysis of metabolic pathways (including polyamine/SSAT-related and others) from simple blood draws. Machine learning models trained on large cohorts achieve strong discrimination for early-stage disease, including against non-cancer lung conditions.

More Information

Accessibility Focus

Accessibility Focus

Non-invasive, cost-conscious approach leveraging existing laboratory infrastructure. Designed to address gaps in current screening uptake and false-positive rates associated with imaging alone.

More Information

Evidence & Validation

"Anchored in large-scale clinical data and peer-reviewed publications."

15,000+

Samples across studies

>0.93

AUROC early-stage (published)

Multi-country

Quebec, France, Germany

Large Cohort Validations

IUCPQ studies exceeding 5,400 subjects; independent validations; participation in the HANSE trial (10,000 participants).

Peer-Reviewed Performance

Multiple publications in IJMS, Frontiers in Oncology, Cancers demonstrating high specificity and accuracy for early-stage NSCLC using metabolite panels + ML.

Recognition & IP

Patents allowed in Canada, Europe, and US. Selected for CTS Beaver Den Innovation Award and other recognitions.

Platform Overview

Primary focus on the Comprehensive Metabolomics Panel; SSAT1 as earlier platform.

Comprehensive Metabolomics Panel (CMP)

Blood-based assay for early lung cancer detection. Validated in large cohorts with strong early-stage performance. Advancing toward laboratory-developed test pathways.

SSAT1 Assay
(Legacy)

Earlier platform using an FDA-approved agent to measure elevated enzyme activity. “Red alert” concept for multiple cancer types; applications in detection, response, and monitoring.

Sign up for the latest BioMark news